September 10, 2026
10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's [...]
September 10, 2026
Tenth SBIR award brings Partillion’s total non-dilutive federal funding to more than $8 million and supports development of Cell-Cell-seq workflows LOS ANGELES -- Partillion Bioscience announced a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences (NIGMS) to expand the company's Cell-Cell-seq workflows. Partillion's 10th SBIR [...]
September 9, 2026
Submission marks the first time data from the AVA™ Emulation System will be evaluated as part of the FDA qualification process, reinforcing confidence in scalable human-relevant liver models BOSTON -- Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, today announced it has submitted its FDA Innovative Science and Technology Approaches for New Drugs (ISTAND) [...]
Bracco Expands BubbleGen Cell Selection with CD3+ T Cell Isolation Kit
September 9, 2026
Microbubble-based technology enables magnetic bead-free cell selection for cell therapy research and development PRINCETON, N.J. -- Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, today announced the expansion of its BubbleGen™ cell selection portfolio with the launch of the BubbleGen CD3+ T Cell Selection Kit. The kit, built on [...]
Countable Labs Continues Global Expansion with New Japanese Distributor
September 9, 2026
Countable Labs' full portfolio is now available through distribution agreement with PRIMETECH PALO ALTO, Calif. -- Countable Labs, developer of Countable PCR, a next-generation PCR technology that enables direct, single-molecule quantification, today announced a distribution partnership with PRIMETECH Corporation to bring its full portfolio of Countable PCR-based solutions to customers in Japan. The agreement follows [...]
My Green Lab Expands ACT Ecolabel Channel Partner Network Ahead of New EU Environmental Claims Rules
September 9, 2026
More than 15 distributors and procurement platforms are aligning around independently verified product sustainability data as new rules reshape environmental claims across the laboratory supply chain SAN DIEGO -- My Green Lab® today announced that more than 15 laboratory product distributors, procurement platforms, and laboratory analytics platforms have joined its ACT® Ecolabel Channel Partner network, expanding [...]
September 9, 2026
Next-generation upgrade strengthens data comparability and compliance—without changing trusted instrumentation San Jose – Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, today announced the launch of Vi-CELL BLU 2.0 Viability Analyzer Software, a major upgrade that enables laboratories to modernize cell viability workflows while maintaining data continuity, [...]
September 9, 2026
Acquisition adds regulated bioanalytical and CMC services, diagnostic reagents, and workflow critical products to support translational, clinical, and commercial development SHAKER HEIGHTS, Ohio -- VION Biosciences ("VION"), a life sciences company building integrated capabilities across research, diagnostics, and drug development workflows, today announced the closing of its acquisition of Prolytix, a provider of regulated bioanalytical [...]
AddLife acquires Unicam Sistemas Analíticos Lda
September 9, 2026
AddLife has acquired Unicam Sistemas Analíticos, a leading Portuguese distributor of advanced analytical laboratory equipment. The company will be included within AddLife’s Business Area Labtech. Unicam Sistemas Analíticos is a Portuguese company distributing advanced analytical laboratory equipment to universities, research institutions and industrial customers. The company has annual revenue of approximately EUR 10 million and [...]
September 9, 2026
Acquisition strengthens Revvity’s position in human-relevant life sciences tools for next-generation GLP-1 and GPCR-targeting therapies for metabolic drug discovery Combines HCD’s human pancreatic beta cell models with Revvity’s capabilities in cell analysis, detection, high-content screening and gene editing Expands Revvity’s ability to support customers across the research-to-clinic continuum, including emerging applications in clinical development and [...]

